{{Rsnum
|rsid=1224141
|Gene=TNFSF13B
|Chromosome=13
|position=108283375
|Orientation=plus
|GMAF=0.1511
|Gene_s=TNFSF13B
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 4.4 | 32.7 | 62.8
| HCB | 0.7 | 4.4 | 94.9
| JPT | 0.0 | 1.8 | 98.2
| YRI | 1.4 | 37.4 | 61.2
| ASW | 10.5 | 24.6 | 64.9
| CHB | 0.7 | 4.4 | 94.9
| CHD | 0.0 | 2.8 | 97.2
| GIH | 0.0 | 24.8 | 75.2
| LWK | 5.5 | 26.4 | 68.2
| MEX | 0.0 | 22.8 | 77.2
| MKK | 4.5 | 32.1 | 63.5
| TSI | 5.9 | 29.4 | 64.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=23845207
|Title=B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome
}}

{{PMID Auto
|PMID=19051265
|Title=Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=19383901
|Title=Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}